ADC Therapeutics reports Q4/FY2024 results: net loss narrows; ZYNLONTA revenue flat; cash runway to H2 2026

ADC Therapeutics SA

Net loss Q4 2024 was $30.7M ($0.29/share) vs $85.0M ($1.03) in Q4 2023; full year net loss $157.8M ($1.62) vs $240.1M ($2.94).
ZYNLONTA net product revenue $16.4M in Q4 and $69.3M for FY 2024, roughly flat vs prior year.
Cash $250.9M at Dec 31, 2024; runway into H2 2026 after $97.4M May 2024 offering.
LOTIS-5 Phase 3 confirmatory trial enrollment completed Dec 2024; data update expected late 2025.
LOTIS-7 Phase 1b: 94% best ORR and 72% CR in r/r DLBCL; dose expansion enrollment completing Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.